Stockreport

Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF Enanta plans a Phase 3 adult study of zelicapavir (N-protein RSV inhibitor) focused on the high-risk “HR3” subgroup (age 75 or COPD/CHF) with a symptom-based RiiQ prima [Read more]